We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+22.52%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$312M
AUM Growth
+$29.5M
Cap. Flow
-$9.09M
Cap. Flow %
-2.91%
Top 10 Hldgs %
68.33%
Holding
49
New
15
Increased
5
Reduced
3
Closed
14

Top Buys

Rank Stock Value
1
ABLX
Ablynx NV
ABLX
+$9.48M
2
FENC icon
Fennec Pharmaceuticals
FENC
+$8.45M
3
CRSP icon
CRISPR Therapeutics
CRSP
+$5.34M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$4.41M
5
LOXO
Loxo Oncology, Inc
LOXO
+$3.86M

Top Sells

Rank Stock Value
1
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$9.25M
2
CTMX icon
CytomX Therapeutics
CTMX
+$8.18M
3
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$7.75M
4
TBPH icon
Theravance Biopharma
TBPH
+$6.16M
5
SYBX
Synlogic
SYBX
+$4.75M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXGN icon
1
Axogen
AXGN
$2.78B
$55.8M 17.85%
1,970,000
– –
BPMC
2
DELISTED
Blueprint Medicines
BPMC
$55.4M 17.75%
735,000
– –
KYNB
3
Kyntra Bio
KYNB
$32.4M
$17.1M 5.46%
14,400
– –
LOXO
4
DELISTED
Loxo Oncology, Inc
LOXO
$14.8M 4.75%
176,300
+46,300
+36% +$3.86M
IMMU
5
DELISTED
Immunomedics Inc
IMMU
$14.5M 4.65%
898,800
– –
CDXS icon
6
Codexis
CDXS
$182M
$14.2M 4.55%
1,700,600
– –
XOMA
7
DELISTED
Xoma
XOMA
$11.4M 3.65%
320,200
– –
ABLX
8
DELISTED
Ablynx NV
ABLX
$10.5M 3.36%
+420,000
New +$9.48M
CORI
9
DELISTED
Corium International, Inc.
CORI
$10.2M 3.26%
1,060,000
+140,000
+15% +$1.49M
SGMO
10
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$9.51M 3.05%
580,000
– –
SBBP
11
DELISTED
Strongbridge Biopharma plc.
SBBP
$9.06M 2.9%
1,250,000
+70,000
+6% +$437K
FENC icon
12
Fennec Pharmaceuticals
FENC
$413M
$8.49M 2.72%
+846,900
New +$8.45M
AGIO icon
13
Agios Pharmaceuticals
AGIO
$2.05B
$7.43M 2.38%
130,000
– –
BOLD
14
DELISTED
Audentes Therapeutics, Inc
BOLD
$6.65M 2.13%
210,000
+30,000
+17% +$824K
CRSP icon
15
CRISPR Therapeutics
CRSP
$5.74B
$6.6M 2.11%
+281,000
New +$5.34M
CBAY
16
DELISTED
Cymabay Therapeutics
CBAY
$6.12M 1.96%
665,000
– –
ARDX icon
17
Ardelyx
ARDX
$986M
$5.94M 1.9%
900,000
+200,000
+29% +$1.19M
FOMX
18
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$5.77M 1.85%
960,000
-182,000
-16% -$1.1M
ARGX icon
19
argenx
ARGX
$66.2B
$5.59M 1.79%
+88,500
New +$2.9M
NKTR icon
20
Nektar Therapeutics
NKTR
$2.55B
$4.78M 1.53%
+5,333
New +$3.15M
RCKT icon
21
Rocket Pharmaceuticals
RCKT
$397M
$4.7M 1.51%
450,500
– –
XLRN
22
DELISTED
Acceleron Pharma
XLRN
$4.31M 1.38%
101,500
– –
RARE icon
23
Ultragenyx Pharmaceutical
RARE
$2.59B
$4.17M 1.34%
+90,000
New +$4.41M
AMRN
24
Amarin Corp
AMRN
$297M
$3.45M 1.1%
+43,000
New +$2.96M
DERM
25
DELISTED
Dermira, Inc.
DERM
$2.78M 0.89%
+100,000
New +$2.65M
1
2

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2017 Portfolio in Review

As of Q4 2017, Opaleye Management held 49 positions worth $312M, up 10% from $283M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Opaleye Management's Q4 2017 filing shows 15 new, 5 increased, 3 reduced and 14 closed positions. Its largest new stake was Ablynx NV: 420,000 shares worth $10.5M. The largest sale was Momenta Pharmaceuticals, Inc., an estimated $9.25M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Communication Services.

  • Opaleye Management's largest Q4 2017 buy was Ablynx NV: 420,000 shares worth $10.5M.
  • Opaleye Management added most to Loxo Oncology, Inc in Q4 2017, an estimated $3.86M increase.
  • Opaleye Management's biggest Q4 2017 reduction was Chimerix, Inc., cutting an estimated $3.82M.
  • Opaleye Management fully exited Momenta Pharmaceuticals, Inc. in Q4 2017, selling an estimated $9.25M.
  • Opaleye Management's ten largest holdings make up 68% of its $312M portfolio in Q4 2017.
  • Opaleye Management opened 15 new positions and closed 14 in Q4 2017.
  • Opaleye Management's portfolio value rose 10% quarter-over-quarter to $312M.

Based on Opaleye Management's 13F filing for Q4 2017, filed 9 Feb 2018.